| Biological Sciences | Lifetime | 43 | US 26 | 99.99 |
| Medical and Health Sciences | Lifetime | 691 | US 360 | 99.97 |
| Immunology | Lifetime | 5 | US 3 | 99.99 |
| Molecular Biology | Lifetime | 120 | US 90 | 99.95 |
| Oncology | Lifetime | 321 | US 183 | 99.47 |
| Epidemiology | Lifetime | 721 | US 369 | 99.06 |
| Hematology | Lifetime | 292 | US 146 | 98.30 |
| Nutrition and Dietetics | Lifetime | 550 | US 228 | 97.58 |
| Rheumatology | Lifetime | 596 | US 274 | 97.17 |
| Pathology and Forensic Medicine | Lifetime | 656 | US 301 | 97.05 |
| Infectious Diseases | Lifetime | 853 | US 432 | 95.94 |
| Nephrology | Lifetime | 432 | US 203 | 95.84 |
| Dermatology | Lifetime | 780 | US 315 | 91.33 |
| Emergency Medicine | Lifetime | 882 | US 468 | 89.06 |
| Immunology | 2021-2025 | 294 | US 98 | 92.82 |
| Immune Response and Inflammation | Lifetime | 2 | US 1 | 99.99 |
| Inflammasome and immune disorders | Lifetime | 1 | US 1 | 99.99 |
| IL-33, ST2, and ILC Pathways | Lifetime | 1 | US 1 | 99.97 |
| Cytokine Signaling Pathways and Interactions | Lifetime | 3 | US 2 | 99.97 |
| Autoimmune and Inflammatory Disorders Research | Lifetime | 6 | US 2 | 99.88 |
| Immune Cell Function and Interaction | Lifetime | 37 | US 26 | 99.94 |
| interferon and immune responses | Lifetime | 34 | US 22 | 99.68 |
| Adipokines, Inflammation, and Metabolic Diseases | Lifetime | 56 | US 29 | 99.62 |
| Hematological disorders and diagnostics | Lifetime | 23 | US 14 | 99.37 |
| Thermal Regulation in Medicine | Lifetime | 18 | US 10 | 99.34 |
| Diabetes and associated disorders | Lifetime | 93 | US 51 | 99.36 |
| Immune cells in cancer | Lifetime | 108 | US 43 | 99.26 |
| Atherosclerosis and Cardiovascular Diseases | Lifetime | 80 | US 41 | 99.27 |
| Toxin Mechanisms and Immunotoxins | Lifetime | 81 | US 47 | 98.76 |
| Kawasaki Disease and Coronary Complications | Lifetime | 36 | US 14 | 98.58 |
| Adenosine and Purinergic Signaling | Lifetime | 98 | US 39 | 98.29 |
| Histone Deacetylase Inhibitors Research | Lifetime | 117 | US 78 | 98.74 |
| Immunotherapy and Immune Responses | Lifetime | 577 | US 306 | 99.06 |
| Inflammatory mediators and NSAID effects | Lifetime | 199 | US 102 | 98.54 |
| Fatty Acid Research and Health | Lifetime | 160 | US 69 | 98.42 |
| Psoriasis: Treatment and Pathogenesis | Lifetime | 136 | US 52 | 98.71 |
| Urticaria and Related Conditions | Lifetime | 147 | US 56 | 98.47 |
| Adrenal Hormones and Disorders | Lifetime | 145 | US 60 | 98.13 |
| Sepsis Diagnosis and Treatment | Lifetime | 390 | US 150 | 98.29 |
| Systemic Lupus Erythematosus Research | Lifetime | 581 | US 206 | 98.25 |
| Whipple's Disease and Interleukins | Lifetime | 18 | US 9 | 97.47 |
| Gout, Hyperuricemia, Uric Acid | Lifetime | 118 | US 45 | 97.15 |
| Macrophage Migration Inhibitory Factor | Lifetime | 69 | US 39 | 96.98 |
| Eicosanoids and Hypertension Pharmacology | Lifetime | 372 | US 197 | 97.66 |
| Pharmacological Effects of Natural Compounds | Lifetime | 497 | US 71 | 96.79 |
| Dermatology and Skin Diseases | Lifetime | 567 | US 168 | 97.37 |
| Cardiac Fibrosis and Remodeling | Lifetime | 222 | US 88 | 96.75 |
| S100 Proteins and Annexins | Lifetime | 386 | US 183 | 96.30 |
| Chemokine receptors and signaling | Lifetime | 284 | US 121 | 95.79 |
| Phagocytosis and Immune Regulation | Lifetime | 260 | US 107 | 95.64 |
| Inflammation biomarkers and pathways | Lifetime | 72 | US 28 | 95.31 |
| Neutrophil, Myeloperoxidase and Oxidative Mechanisms | Lifetime | 454 | US 210 | 96.24 |
| Dialysis and Renal Disease Management | Lifetime | 790 | US 286 | 96.66 |
| NF-κB Signaling Pathways | Lifetime | 494 | US 199 | 95.77 |
| Biomarkers in Disease Mechanisms | Lifetime | 553 | US 147 | 85.73 |
| Dermatological and COVID-19 studies | Lifetime | 452 | US 124 | 83.40 |
| Immune responses and vaccinations | Lifetime | 822 | US 266 | 82.13 |
| Fractal and DNA sequence analysis | Lifetime | 879 | US 166 | 68.96 |
| Inflammasome and immune disorders | 2021-2025 | 62 | US 15 | 96.73 |
| Immune cells in cancer | 2021-2025 | 636 | US 131 | 90.75 |
| Immune responses and vaccinations | 2021-2025 | 172 | US 48 | 83.52 |
| IL-33, ST2, and ILC Pathways | 2021-2025 | 692 | US 239 | 78.37 |
